Methods:
Subjects with kidney disease, heart disease, liver disease, diabetes mellitus, cancer status, obesity, (body mass index (BMI) ≥30 kg.m2) and autoimmune disease were excluded clinically and serologically.The sTRAIL levels of pre- and post-treated allergic rhinoconjunctivitis patients (n=25) were compared to age and sex-matched healthy individuals (n=25). sTRAIL levels were measured by ELISA. The skin prick test (SPT) were recorded before and after treatment.
Results:
The sTRAIL levels between the pre-treated and control groups were significantly different (p < 0,0001). However, there was no significant difference between post-treated
group and healthy individuals (p = 0,801). SPT was a statistically significant difference between the values of the research group before and after immunotherapy (Grasses mixture, Barley mixture, Oleaauropeae, D. Pteronyssinus, D. farinae).
Conclusions:
Allergen- spesific immunotherapy treatment significantly reduced the nasal symptom score across all group I patients studied . In this study, SPT was a statistically significant difference between the values of the research group before and after immunotherapy (Grasses mixture, Barley mixture, Oleaauropeae, D.Pteronyssinus, D. farinae).
The sTRAIL levels were decreased after allergen- spesific immunotherapy as to healthy individuals’ levels. be a marker of efficacy of immunotherapy in
allergic rhinoconjunctivitis patients.